首頁 > 市場調查報告書 > 製藥

神經疾病

市場調查報告書

商品編碼

1649462

重症肌無力治療市場：預測（2025-2030）

Myasthenia Gravis Treatment Market - Forecasts from 2025 to 2030

出版日期: 2025年01月07日 | 出版商:

Knowledge Sourcing Intelligence | 英文 142 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

重症肌無力治療市場預計將以 7.14% 的複合年成長率成長，到 2025 年達到 19.73 億美元，到 2030 年達到 27.85 億美元。

重症肌無力是一種慢性神經肌肉疾病，其特徵是隨意肌無力，主要由神經和肌肉之間傳遞的訊號出現問題引起。重症肌無力的治療方法包括多種藥物治療，包括輸血、類固醇和肌肉強化藥物，以及手術介入。重症肌無力是一種影響人體隨意肌的慢性自體免疫疾病。近年來，全球自體免疫疾病病例顯著增加，尤其是老年族群。此外，預計預測期內製藥業研發的不斷加強將進一步推動市場成長。

推動重症肌無力治療市場的因素：

自體免疫疾病盛行率不斷增加：全球自體免疫疾病盛行率不斷增加是推動重症肌無力治療市場擴張的關鍵因素。當免疫系統錯誤地攻擊健康組織時，就會發生自體免疫疾病，而重症肌無力則會破壞肌肉和神經之間的溝通。根據牛津大學的最新資料，全球約有10%的人口受到這些疾病的影響，其中女性為13%，男性為7%。

影響重症肌無力治療市場的地理趨勢：

北美顯著成長：預計預測期內北美地區將佔據重症肌無力治療市場的大部分佔有率。這一成長主要得益於美國和加拿大等國家的製藥技術和研發生態系統的進步。美國是藥品和技術的主要生產國，支持了重症肌無力治療市場的擴大。

此外，旨在加強藥品研究和開發的政府措施預計將對市場成長做出重大貢獻。該地區神經系統疾病的高發性推動了對有效治療的需求，預計未來幾年阿茲海默症症等疾病將影響數百萬人。總而言之，由於全球自體免疫疾病盛行率不斷上升、人們對早期診斷和治療方案的認知不斷提高、製藥技術的進步以及政府（尤其是北美政府）的支持性舉措，重症肌無力治療市場預計將大幅成長，推動這一重要醫療保健領域的創新。

為什麼要購買這份報告？

深刻分析：獲得深入的市場洞察，涵蓋主要和新興地區，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、垂直行業和其他子區隔。
競爭格局：了解全球主要企業所採用的策略策略，並了解正確策略帶來的潛在市場滲透率。
市場趨勢和促進因素：探索動態因素和關鍵市場趨勢以及它們將如何影響市場的未來發展。
可行的建議：利用洞察力做出策略決策，在動態環境中開闢新的業務流和收益。
受眾廣泛：對於新興企業、研究機構、顧問公司、中小企業和大型企業都有益且具有成本效益。

它有什麼用途？

產業與市場分析、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本支出決策、法律規範與影響、新產品開發、競爭影響

研究範圍

2022 年至 2030 年的實際資料和預測
成長機會、挑戰、供應鏈前景、法規結構、顧客行為、趨勢分析
競爭定位、策略與市場佔有率分析
各地區（包括細分市場和國家）的收益成長和預測分析
公司概況（策略、產品、財務、主要發展等）

Myasthenia gravis is a chronic neuromuscular disease characterized by weakness in the voluntary muscles, primarily caused by issues with the signals sent between nerves and muscles. Treatment options for myasthenia gravis include various medications and surgical interventions, such as blood transfusions, steroids, and muscle strengtheners. The global myasthenia gravis treatment market is anticipated to experience significant growth due to the increasing prevalence of autoimmune diseases.As a chronic autoimmune disorder, myasthenia gravis affects the voluntary muscles of the body. The rise in global cases of autoimmune diseases has been notable in recent years, particularly among older adults. Additionally, ongoing research and development within the pharmaceutical sector are expected to further drive market growth during the forecast period.

Drivers of the Myasthenia Gravis Treatment Market:

Increasing Prevalence of Autoimmune Disorders: The growing global incidence of autoimmune disorders is a key factor fueling the expansion of the myasthenia gravis treatment market. Autoimmune disorders occur when the immune system mistakenly attacks healthy tissues, and myasthenia gravis disrupts communication between muscles and nerves. Recent data from the University of Oxford indicates that approximately 10% of the global population is affected by these diseases, with 13% of women and 7% of men impacted.

Geographical Trends Shaping the Myasthenia Gravis Treatment Market:

Significant Growth in North America: The North American region is projected to hold a substantial share of the myasthenia gravis treatment market during the forecast period. This growth is primarily driven by advancements in pharmaceutical technologies and research and development ecosystems in countries like the USA and Canada. The USA is a leading producer of pharmaceutical drugs and technologies, which supports market expansion for myasthenia gravis treatments.

Moreover, government initiatives aimed at enhancing pharmaceutical research and development are expected to significantly contribute to market growth. The high prevalence of neurological disorders in this region further drives demand for effective treatments, with projections indicating that there will be millions affected by conditions like Alzheimer's disease in the coming years.In summary, the myasthenia gravis treatment market is poised for substantial growth due to rising prevalence rates of autoimmune disorders globally, increased awareness about early diagnosis and treatment options, advancements in pharmaceutical technologies, and supportive governmental initiatives-particularly within North America-that foster innovation in this critical healthcare sector.

Reasons for buying this report:-

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data & forecasts from 2022 to 2030
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

The Myasthenia Gravis Treatment market is segmented and analyzed as follows:

By Application

Medication
Pyridostigmine
Cyclosporine
Azathioprine
Surgery
Other

By End User

Hospitals
Clinics
Others
By Geography
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
Spain
United Kingdom
France
Italy
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
China
Japan
Australia
India
Indonesia
Thailand
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base and Forecast Years Timeline
1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY

2.1. Research Design
2.2. Research Process

3. EXECUTIVE SUMMARY

3.1. Key Findings

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. The Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
4.5. Analyst View

5. MYASTHENIA GRAVIS TREATMENT MARKET BY APPLICATION

5.1. Introduction
5.2. Medication
5.3. Surgery
5.4. Other

6. MYASTHENIA GRAVIS TREATMENT MARKET BY END-USER

6.1. Introduction
6.2. Hospital
6.3. Clinics
6.4. Others

7. MYASTHENIA GRAVIS TREATMENT MARKET BY GEOGRAPHY

7.1. Introduction
7.2. North America
- 7.2.1. By Application
- 7.2.2. By End User
- 7.2.3. By Country
  - 7.2.3.1. United States
  - 7.2.3.2. Canada
  - 7.2.3.3. Mexico
7.3. South America
- 7.3.1. By Application
- 7.3.2. By End User
- 7.3.3. By Country
  - 7.3.3.1. Brazil
  - 7.3.3.2. Argentina
  - 7.3.3.3. Others
7.4. Europe
- 7.4.1. By Application
- 7.4.2. By End User
- 7.4.3. By Country
  - 7.4.3.1. Germany
  - 7.4.3.2. Spain
  - 7.4.3.3. United Kingdom
  - 7.4.3.4. France
  - 7.4.3.5. Others
7.5. Middle East and Africa
- 7.5.1. By Application
- 7.5.2. By End User
- 7.5.3. By Country
  - 7.5.3.1. Saudi Arabia
  - 7.5.3.2. South Africa
  - 7.5.3.3. Others
7.6. Asia Pacific
- 7.6.1. By Application
- 7.6.2. By End User
- 7.6.3. By Country
  - 7.6.3.1. China
  - 7.6.3.2. Japan
  - 7.6.3.3. Australia
  - 7.6.3.4. India
  - 7.6.3.5. South Korea
  - 7.6.3.6. Indonesia
  - 7.6.3.7. Others